Elsevier

Clinical Therapeutics

Volume 18, Issue 6, November–December 1996, Pages 1080-1092
Clinical Therapeutics

Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine

https://doi.org/10.1016/S0149-2918(96)80063-4Get rights and content

Abstract

We have previously described the inhibition of human immunodeficiency virus serotype 1 (HIV-1) using the antimalarial hydroxychloroquine (HCQ), a weak base that inhibits the posttranslational modification of glycoprotein 120 (gp120) in T cells and monocytes. The mechanism of inhibition of gp120 production was presumed to be the ability of HCQ to increase endosomal pH and therefore alter enzymes required for gp120 production. To further clarify this action, we have determined the effect of HCQ and its enantiomers on endosomal pH. Pretreatment of cells with HCQ and the levo- and dextro-enantiomers at concentrations demonstrated to suppress anti—HIV-1 activity increased endosomal pH to levels similar to increases seen with chloroquine and ammonium chloride, two other weak bases, and decreased gp120 production. The dextro- and levo-enantiomers suppressed HIV-1 replication to a similar extent and were no more toxic than racemic HCQ. We next compared the anti—HIV-1 effect of HCQ with zidovudine (ZDV) in both newly and chronically HIV-1—infected T-cell and monocytic cell lines (63 and 63HIV). HCQ suppressed HIV-1 replication in a dose-dependent manner in both recently and chronically infected T-cell and monocytic cell lines. In contrast, ZDV pretreatment had potent anti—HIV-1 activity in the newly infected T and monocytic cells but not in chronically infected cells. An additive effect of HCQ with ZDV was observed in the newly infected T and monocytic cells but not in the chronically infected cells. Although the anti—HIV-1 effect of HCQ was less than that of ZDV, HCQ may still be potentially useful either as an alternative HIV-1 treatment or in combination with other anti—HIV-1 agents, especially in patients who have rheumatic manifestations of HIV-1 infection.

References (27)

  • K Oda et al.

    Weakly basic amines inhibit the proteolytic conversion of proalbumin to albumin in cultured rat hepatocytes

    Eur J Biochem

    (1985)
  • SE Tett et al.

    Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study

    J Rheumatol

    (1993)
  • GS Panayi et al.

    Action of chloroquine phosphate in rheumatoid arthritis. Immunosuppressive effects

    Ann Rheum Dis

    (1973)
  • Cited by (85)

    • Rheumatoid arthritis and HIV-associated arthritis: Two sides of the same coin or different coins

      2022, Best Practice and Research: Clinical Rheumatology
      Citation Excerpt :

      HCQ demonstrated anti-retroviral properties in one series; however, the doses used were much higher than used as standard of care in rheumatology practice [29]. It was postulated that the anti-retroviral properties of HCQ result from the drugs ability to increase the endosomal pH that inhibits the post-observational modification of glycoprotein (GP)120 [30–33]. This may be an added benefit to patients with RA and HIV infection.

    • Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19

      2020, Pharmacology and Therapeutics
      Citation Excerpt :

      Since CQ prevents endosomal acidification, the elevated pH level results in inhibition of lysosome functions, thereby inhibiting the activity of viruses such as influenza B virus (Shibata et al., 1983) and hepatitis A virus (M. A. A. Al-Bari, 2017). Second, CQ may inhibit the post-translational modification of the virus envelope glycoprotein by interfering with the activity of specific enzymes that require low pH (Chiang et al., 1996; Rolain, Colson, & Raoult, 2007). Another mechanism may be attributed to the immunomodulatory effect of CQ.

    • Antimalarials as Antivirals for COVID-19: Believe it or Not!

      2020, American Journal of the Medical Sciences
    • Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations

      2020, European Journal of Pharmacology
      Citation Excerpt :

      Potential antimalarial drugs such as chloroquine (CQ) and hydroxychloroquine (HCQ) have been long used to prophylaxis and treatment of malaria (Warhurst et al., 2003). Although, administration of CQ and HCQ have extended to several inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and against some viruses including human immunodeficiency virus (HIV), and influenza (Chiang et al., 1996; Ooi et al., 2006). The current pandemy of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a high morbidity and mortality with 17, 189, 755 confirmed cases and 670,256 deaths until July 30, 2020 (worldometers, 2020).

    View all citing articles on Scopus
    View full text